Vanguard Group Inc Point Biopharma Global Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.67 - $9.71 $1.42 Million - $2.06 Million	212,433 Added 4.77%	4,667,786 $31.1 Million
Q2 2023 Aug 14, 2023	BUY	$6.86 - $10.86 $189,116 - $299,388	27,568 Added 0.62%	4,455,353 $40.4 Million
Q1 2023 May 15, 2023	BUY	$6.78 - $8.1 $243,144 - $290,482	35,862 Added 0.82%	4,427,785 $32.2 Million
Q4 2022 Feb 10, 2023	BUY	$5.72 - $9.78 $2.95 Million - $5.05 Million	516,601 Added 13.33%	4,391,923 $32 Million
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $3.09 Million - $4.4 Million	426,617 Added 12.37%	3,875,322 $30 Million
Q2 2022 Aug 12, 2022	BUY	$5.6 - $9.5 $1.39 Million - $2.36 Million	248,490 Added 7.76%	3,448,705 $23.5 Million
Q1 2022 May 13, 2022	BUY	$5.46 - $8.13 $9.69 Million - $14.4 Million	1,774,040 Added 124.39%	3,200,215 $25.5 Million
Q4 2021 Feb 14, 2022	SELL	$4.83 - $9.75 $161,331 - $325,669	-33,402 Reduced 2.29%	1,426,175 $7.99 Million
Q3 2021 Nov 12, 2021	BUY	$7.42 - $11.26 $10.8 Million - $16.4 Million	1,459,577 New	1,459,577 $11.2 Million

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.